Melbourne, Victoria, Australia – 6 December 2019
Trajan Scientific and Medical (Trajan) announce the appointment of two new roles in their expanding Microsampling business to support global adoption of the portfolio. Led by Dr Anne Collins, the Microsampling business is focused on enabling samples that would not or could not otherwise be taken, to drive information-rich decision making.
The creation of two new roles at Trajan see Dr Florian Lapierre step into the role of Senior Product Specialist, and Pawanbir Singh M.D. as Business Development Manager - Microsampling, UK and Europe. Both roles highlight the evolution of the market and increased demand for patient centric microsampling technologies.
Located in Fribourg, Switzerland, Dr Lapierre is responsible for strengthening the connection across functional departments within Trajan by supporting the growing market for microsampling, product knowledge, and assisting with needs for future product development.
Dr Lapierre joined Trajan in 2015 as a Research Scientist within ASTech (ARC Training Centre for Portable Analytical Separation Technologies); during this time he developed the initial hemaPEN® concept, and has been instrumental in the evolution of the technology.
UK-based Dr Singh, is a Medical Doctor who is responsible for developing commercialization blueprints and leading new technology adoption, support growing interest in patient centric sampling technologies.
Dr Singh joined Trajan in 2015 as Market Manager for Health, having previously worked for Leica Biosystems and STEMCELL Technologies.
Dr Collins said, “I’m excited to have Dr Lapierre and Dr Singh strengthen the team in their new roles, and have them focused on leading the technology adoption of Trajan’s portfolio including the hemaPEN technology platform.”
hemaPEN provides a convenient sampling procedure for collection and storage of four dried blood spot (DBS) samples to drive information-rich decision making. Unlike conventional DBS sampling tools, hemaPEN enables collection of an accurate and precise fixed micro-volume, and is designed to maintain sample integrity for quantitative analysis.
Stephen Tomisich, CEO advised that, “The technologies Trajan has developed have real potential to spark changes in approaches to healthcare that will truly deliver upon the Trajan vision - science that benefits people.”
To learn more about Trajan’s microsampling technologies and capabilities visit www.trajanscimed.com/microsampling.
Press release [PDF]
Media contact information
Trajan Scientific and Medical
Tel: +44 (0) 1908 568 844
The hemaPEN® is a device supplied for research purposes only. This device is not for therapeutic or diagnostic use.
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.